No results found for “”
No results found for filter “”
-
Statements & press releases 18.07.25
EFPIA preliminary response to the European Commission Multiannual Financial Framework package
To turn life science competitiveness goals into reality, Europe needs a Multiannual Financial Framework (MFF) that includes ambitious funding for health...
Read Article -
EFPIA News 16.07.25
EFPIA submits GDPR Code of Conduct for formal assessment
EFPIA is pleased to announce the submission of its GDPR Code of Conduct on Clinical Trials and Pharmacovigilance to the Belgian Data Protection Authority...
Read Article -
Statements & press releases 16.07.25
Clinical trial community seek urgent implementation of Life Science Strategy, as research becomes increasingly...
A broad group of organisations, working in the European clinical trial sector, have issued a warning to policy makers, that without urgent implementation...
Read Article -
Blog articles 09.07.25
Transforming regulatory pathways: A path to swift patient access (Guest Blog)
In today’s fast-paced world of medical advancement, regulatory frameworks have a crucial role to act as a key enabler for timely access to innovation for...
Read Article -
EFPIA News 04.07.25
EFPIA Position on the Critical Medicines Act
By embedding flexibility, coordination, and proportionate regulation into its implementation, the Act can support a future-ready pharmaceutical ecosystem...
Read Article -
Statements & press releases 02.07.25
EU Life science strategy: a springboard for European life sciences
For Europe to truly lead it needs to invest in medicines, attract investment, accelerate turning that investment into new treatments and economic growth...
Read Article -
Statements & press releases 26.06.25
Rapidly shifting geopolitics provides opportunity for Europe to reset and to lead in global life sciences,...
By choosing to lead, Europe can translate the region’s scientific excellence into cutting edge therapies, those therapeutic advances into better health...
Read Article -
Blog articles 26.06.25
Ten years of evolving transparency in industry-healthcare relationships in the UK (Guest blog)
After a decade of the pharmaceutical industry publicly declaring payments, more health professionals than ever are being transparent about these crucial...
Read Article -
Blog articles 25.06.25
Disclosure of payments: How transparency works in Spain (Guest blog)
Spain is a leading example of an industry embracing disclosure, building trust and nurturing transparent collaboration
Read Article -
Blog articles 23.06.25
Putting patients first: why transparency in industry partnerships matters (Guest blog)
Transparent practices help dispel misconceptions, ensure accountability, and demonstrate that collaboration serves shared goals—not hidden agendas.
Read Article -
Blog articles 20.06.25
A decade of disclosure
Strengthening trust, transparency and collaboration
Read Article -
Blog articles 18.06.25
Working together to build a better Product Information Leaflet (Guest blog)
In response to the evolving landscape of electronic Product Information (ePI) and the currently ongoing revision of the EU General Pharma Legislation,...
Read Article
No results found for “”
No results found for filter “”
-
EFPIA News 16.07.25
EFPIA submits GDPR Code of Conduct for formal assessment
EFPIA is pleased to announce the submission of its GDPR Code of Conduct on Clinical Trials and Pharmacovigilance to the Belgian Data Protection Authority...
Read Article -
EFPIA News 04.07.25
EFPIA Position on the Critical Medicines Act
By embedding flexibility, coordination, and proportionate regulation into its implementation, the Act can support a future-ready pharmaceutical ecosystem...
Read Article -
EFPIA News 11.06.25
EFPIA response to the European Commission call for evidence on the EU Biotech Act
To make the EU more attractive for researching, developing and manufacturing new technologies, we urge coordinated and urgent action across several areas. ...
Read Article -
EFPIA News 17.03.25
Harnessing RWE to transform healthcare decision-making in Europe
EFPIA vision on the role and use of RWE in decision-making
Read Article -
EFPIA News 29.01.25
Medicine shortages: EFPIA proposal for action
Together, all stakeholders share a responsibility and commitment to building resilient supply chains that ensure patients receive the medicines they need....
Read Article -
EFPIA News 24.01.25
EFPIA response to the adoption of the European Health Data Space (EHDS)
EFPIA welcomes the adoption of the European Health Data Space (EHDS) by the Council of the EU, marking a significant step forward in leveraging health...
Read Article -
EFPIA News 15.01.25
IMAGINE if Europe was a leader in life sciences
Just imagine if the EU Life Sciences Sector developed the next generation of therapies, attracted the best scientific research, developed the brightest...
Read Article -
EFPIA News 08.01.25
With NIRO navigate innovation and research opportunities
2025 has arrived, bringing a host of opportunities for R&I! Find which one(s) could best help you pursue groundbreaking work.
Read Article -
EFPIA News 18.11.24
Breaking barriers in Rare Disease Research: The Rare Disease Moonshot at two years
Rare diseases impact millions globally, yet fewer than 5% of the over 7,000 identified have treatments, underscoring an urgent need for action. The Rare...
Read Article -
EFPIA News 26.09.24
EFPIA position on opt-out in the EHDS Regulation
EFPIA stresses the importance of avoiding fragmentation and bias, clarifying the scope of the opt-out by limiting it to personal data and creating a centralised...
Read Article -
EFPIA News 11.07.24
NIRO: Navigating innovation and research opportunities
A new tool to help navigate the complex world of health R&I funding programmes.
Read Article -
EFPIA News 08.07.24
Breaking down barriers: Making cross-border access to clinical trials a reality
Collaborative effort by EFGCP and EFPIA develops action plan to address participation barriers in Europe
Read Article
No results found for “”
No results found for filter “”
-
Statements & press releases 18.07.25
EFPIA preliminary response to the European Commission Multiannual Financial Framework package
To turn life science competitiveness goals into reality, Europe needs a Multiannual Financial Framework (MFF) that includes ambitious funding for health...
Read Article -
Statements & press releases 16.07.25
Clinical trial community seek urgent implementation of Life Science Strategy, as research becomes increasingly...
A broad group of organisations, working in the European clinical trial sector, have issued a warning to policy makers, that without urgent implementation...
Read Article -
Statements & press releases 02.07.25
EU Life science strategy: a springboard for European life sciences
For Europe to truly lead it needs to invest in medicines, attract investment, accelerate turning that investment into new treatments and economic growth...
Read Article -
Statements & press releases 26.06.25
Rapidly shifting geopolitics provides opportunity for Europe to reset and to lead in global life sciences,...
By choosing to lead, Europe can translate the region’s scientific excellence into cutting edge therapies, those therapeutic advances into better health...
Read Article -
Statements & press releases 04.06.25
EU Council’s decision on pharmaceutical legislation: A missed opportunity for European innovation
EFPIA's reaction to the GPL announcement from the EU Council of Ministers
Read Article -
Statements & press releases 14.05.25
Almost 100 new medicine approvals tracked; new data gives clearest picture yet of delays for patients ...
EFPIA also publishes first report aimed specifically as a catalyst for action to tackle inequalities faced by smaller countries.
Read Article -
Statements & press releases 08.05.25
EFPIA’s recommendations for the future EU Multiannual Financial Framework
The future MFF should support the life sciences research and innovation ecosystem, ensure the competitiveness of the EU regulatory system and foster the...
Read Article -
Statements & press releases 07.05.25
New data shows no shift in access to medicines for millions of Europeans
EFPIA says perennial state of medicines inequality requires rapid action from multiple partners to address numerous interlinked barriers and delays to...
Read Article -
Statements & press releases 25.04.25
New research shows voucher system to drive R&D in antimicrobial resistance (AMR) is 45% less expensive...
Antimicrobial resistance (AMR) is one of the world’s most pressing health emergencies. Yet despite the urgent need, private investment in antimicrobial...
Read Article -
Statements & press releases 17.04.25
A Strategy for European Life Sciences
EFPIA welcomes the Commission initiative to develop a robust EU Life Sciences Strategy to strengthen Europe competitiveness and close the innovation gap...
Read Article -
Statements & press releases 08.04.25
Pharma CEOs alert President von der Leyen to risk of exodus to the US
CEOs of the research-based pharmaceutical industry issued a stark warning to President von der Leyen that unless Europe delivers rapid, radical policy...
Read Article -
Statements & press releases 19.03.25
Cancer care 2025: an overview of cancer outcomes data across Europe
Cancer survival rates improve across Europe, but disparities between countries remain
Read Article
No results found for “”
No results found for filter “”
-
Blog articles 09.07.25
Transforming regulatory pathways: A path to swift patient access (Guest Blog)
In today’s fast-paced world of medical advancement, regulatory frameworks have a crucial role to act as a key enabler for timely access to innovation for...
Read Article -
Blog articles 26.06.25
Ten years of evolving transparency in industry-healthcare relationships in the UK (Guest blog)
After a decade of the pharmaceutical industry publicly declaring payments, more health professionals than ever are being transparent about these crucial...
Read Article -
Blog articles 25.06.25
Disclosure of payments: How transparency works in Spain (Guest blog)
Spain is a leading example of an industry embracing disclosure, building trust and nurturing transparent collaboration
Read Article -
Blog articles 23.06.25
Putting patients first: why transparency in industry partnerships matters (Guest blog)
Transparent practices help dispel misconceptions, ensure accountability, and demonstrate that collaboration serves shared goals—not hidden agendas.
Read Article -
Blog articles 20.06.25
A decade of disclosure
Strengthening trust, transparency and collaboration
Read Article -
Blog articles 18.06.25
Working together to build a better Product Information Leaflet (Guest blog)
In response to the evolving landscape of electronic Product Information (ePI) and the currently ongoing revision of the EU General Pharma Legislation,...
Read Article -
Blog articles 12.06.25
From Principle to Practice: Paving the Future Beyond Animal Testing
Helping to shape a roadmap to phase out animal testing for chemical safety assessments
Read Article -
Blog articles 04.06.25
Health as a strategic investment: Highlights from the 14th Value of Innovation Conference (Guest blog)...
What if we stopped seeing health as a cost and started treating it as a long-term investment?
Read Article -
Blog articles 22.05.25
How public-private partnerships are optimising the research ecosystem
Clinical Trials: The Innovative Health Initiative is showing the power of collaboration as a catalyst for change in European research
Read Article -
Blog articles 21.05.25
Cross-border trials: ‘Not every patient is as lucky as me’
Patient story: travelling to Germany for a clinical trial offered Savo Pilipovic access to life-saving melanoma therapy. But his story is the exception,...
Read Article -
Blog articles 20.05.25
Clinical trials: Good for patients, good for Europe (Guest blog)
The EU Biotech Act is a unique opportunity to strengthen Europe’s clinical research ecosystem and regain global competitiveness in life sciences. We present...
Read Article -
Blog articles 28.04.25
Unmet medical needs in chronic cardiovascular diseases: Innovative approaches to therapeutic adherence...
A narrow definition of unmet medical need overlooks the potential of existing medicines to improve outcomes for patients
Read Article